geoffrey modest medical blogs

  A recent study found that lenacapavir was a very effective med to prevent HIV infection in cisgender women (see   hiv pre-exp proph lenacapavir cisgender women NEJM2024  in dropbox, or DOI: 10.1056/NEJMoa2407001   Details : -- 5338 HIV-negative women in South Africa and Uganda were recruited into a phase 3, double-blind, randomized controlled trial of 3 groups to assess pre-exposure prophylaxis against HIV (PrEP):     -- subcutaneous lenacapavir 927mg every 26 weeks (with a window of up to 7 days) plus placebo tablets for F/TAF and F/TDF     -- daily oral F/TAF (emtricitabine-tenofovir alafenamide) plus placebo injections     -- daily oral F/TDF (emtricitabine-tenofovir disoproxil fumarate) plus placebo injections, serving as an active control -- the background in these countries: at least 3.5 adolescent girls and young women per 100 person-years developed incident HIV infections if not using PrEP -- the participants in ...

  A couple of new articles on treatment of Alzheimer’s disease came out in the last couple of weeks. The first is an investigative report on some monoclonal antibodies that delayed symptoms of Alzheimer’s for a few months but at a remarkably high risk of very serious adverse events in an ethically fraught study; the second is potentially redeploying  a schizophrenia drug as a treatment for Alzheimer’s ---------------------------------------------------------------------   New York times had a very recent and remarkably disturbing article on new FDA-approved Alzheimer’s Disease drugs that had significantly more serious adverse effects than benefits: https://www.nytimes.com/2024/10/23/health/alzheimers-drug-brain-bleeding.html?smid=nytcore-ios-share&referringSource=articleShare   Details : -- the drugmaker Eisai in 2021 recruited 2000 volunteers to test their experimental Alzheimer’s drug BAN2401, a monoclonal antibody targeted to eliminate brain beta-a...